CAS Search
Related Chemical Product
Buy Chemical NO: 9012-76-4
  • Urgent Purchase CAS NO.:9012-76-4
  • Please post your buying leads! Our suppliers will contact you later!
  • For suppliers to better understand your request, enter more info here.

* Product Name:
CAS No.:
* Quantity:
 
 Metric Ton     Kilogram    Gram    Pound
* Valid For:
 5 Days    15    1 Month    3 Month    6 Month    1 Year
* Description:

Max 2000 characters.  Please enter detailed description for the product.
* Email:
 

Chitosan ( CASNO:9012-76-4 )

Identification and Related Records
Name:
Chitosan
CAS Registry number:
9012-76-4
Synonyms:
Flonac C
Chitosan H
Marinkaito F 05N
Marinkaito F 05S
KW 5
TKS 250N
Sea Cure 123
FCM 117
SK 10 (polysaccharide)
HC 1 (polysaccharide)
North Chitosan MC 1
OTS 2
Sea Cure 143
SK 200
Sea Cure 340
HI-DENSITY CHITOSAN
Chitopearl BCW 3505
Chiton (molluscan common name)Chitopearl 3510
Chitopearl BCW 3507
Hiset KW 5
WOT Recovery Floc T
Kytex M
Sea Cure 243
Chitosan EL
Hydagen HCMF
Profloc 320
EINECS(EC#):
222-311-2
Molecular Formula:
Unspecified
Molecular Weight:
179.17112
Inchi:
InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1
InChIKey:
MSWZFWKMSRAUBD-QZABAPFNSA-N
Canonical SMILES:
C(C1C(C(C(C(O1)O)N)O)O)O
Isomers smiles:
C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)O
Chemical and Physical Properties
Appearance:
faintly beige solid
Density:
1.75g/cm3
Melting Point:
88 deg C
Refractive Index:
1.7
Water:
insoluble in water
Solubilities:
insoluble in water
Stability:
Stable. Incompatible with strong oxidizing agents.
Storage temp:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Computed Properties:
Molecular Weight:179.17112 [g/mol]
Molecular Formula:C6H13NO5
XLogP3-AA:-2.8
H-Bond Donor:5
H-Bond Acceptor:6
Rotatable Bond Count:1
Exact Mass:179.079373
MonoIsotopic Mass:179.079373
Topological Polar Surface Area:116
Heavy Atom Count:12
Formal Charge:0
Complexity:155
Isotope Atom Count:0
Defined Atom Stereocenter Count:5
Undefined Atom Stereocenter Count:0
Defined Bond Stereocenter Count:0
Undefined Bond Stereocenter Count:0
Covalently-Bonded Unit Count:1
Feature 3D Acceptor Count:5
Feature 3D Donor Count:5
Feature 3D Cation Count:1
Feature 3D Ring Count:1
Effective Rotor Count:2.2
Conformer Sampling RMSD:0.6
CID Conformer Count:6
Safety and Handling
Hazard Codes:
Xn
Risk Statements:
20/21/22-36/37/38
Safety Statements:
S24/25
Safety:
Hazard Codes:Xn
Risk Statements:20/21/22-36/37/38
20/21/22:Harmful by inhalation, in contact with skin and if swallowed
36/37/38:Irritating to eyes, respiratory system and skin
Safety Statements:24/25-36-26
24/25:Avoid contact with skin and eyes
36:Wear suitable protective clothing
26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice
WGK Germany:-
Formulations/Preparations:
The three forms of glucosamine available commercially are glucosamine hydrochloride, glucosamine sulfate and N-acetyl glucosamine.
Specification:
The Chitosan, with the cas registry number 9012-76-4, is a kind of white colorless solid. This is stable but incompatible with strong oxidizing agents. And its product categories are including Miscellaneous Natural Products; Biochemistry; Polysaccharides; Sugars; Nutritional Supplements; Dextrins Sugar & Carbohydrates. The physical properties of this chemical are as follows: (1)# of Rule of 5 Violations: 3; (2)ACD/BCF (pH 5.5): 1; (3)ACD/BCF (pH 7.4): 1; (4)ACD/KOC (pH 5.5): 1; (5)ACD/KOC (pH 7.4): 1; (6)#H bond acceptors: 48; (7)#H bond donors: 37; (8)#Freely Rotating Bonds: 55; (9)Polar Surface Area: 808; (10)Index of Refraction: 1.701; (11)Molar Refractivity: 336.803 cm3; (12)Molar Volume: 870.564 cm3; (13)Polarizability: 133.519 ×10-24 cm3; (14)Surface Tension: 122.211 dyne/cm; (15)Density: 1.753 g/cm3; (16)Exact Mass: 179.079373; (17)MonoIsotopic Mass: 179.079373; (18)Topological Polar Surface Area: 116; (19)Heavy Atom Count: 12; (20)Complexity: 155. The production method of this chemical is below: Add 20g Chitosan into the 300mL 50% NaOH solvent and wait for its complete infiltration; Then heat to 95℃ for about 1.5 hours, filter out the alkali liquor and then wash to be neutral; Lastly cool and dry to have colorless transparent schistose products 15.6g. As to its usage, it is widely applied in many ways. It could be used as antistaling agent which is usually used in food industry, and thickening agent, flocculating agent; It could also be used in pharmaceutic, agricultural seed, daily expenses, waste water treatment. When you are dealing with this chemical, you should be very cautious. Being a kind of harmful chemicals, it may cause damage to health. If by inhalation, in contact with skin and if swallowed, it is dangerous. Then it is irritating to eyes, respiratory system and skin. Therefore, you shoud take the following instructions. Wear suitable protective clothing, and then avoid contacting with skin and eyes. If in case of contact with eyes, rinse immediately with plenty of water and seek medical advice. In addition, you could convert the following datas into the molecular structure:
(1)Canonical SMILES: C(C1C(C(C(C(O1)O)N)O)O)O
(2)Isomeric SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)O
(3)InChI: InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,-/m1/s1
(4)InChIKey: MSWZFWKMSRAUBD-QZABAPFNSA-N?
Octanol/Water Partition Coefficient:
log Kow = -4.2 (est)
Disposal Methods:
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
Use and Manufacturing
Use and Manufacturing:
Methods of Manufacturing

Found in chitin, in mucoproteins, and in mucopolysaccharides.
Usage:
Claimed to have the ability to retain fats and cholesterol in the stomach.
Biomedical Effects and Toxicity
Therapeutic Uses:
Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. 1583 patients with symptomatic knee osteoarthritis /were randomly assigned/ to receive 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1229] vs. moderate to severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24. The mean age of the patients was 59 years, and 64 percent were women. Overall, glucosamine and chondroitin sulfate were not significantly better than placebo in reducing knee pain by 20 percent. As compared with the rate of response to placebo (60.1 percent), the rate of response to glucosamine was 3.9 percentage points higher (P=0.30), the rate of response to chondroitin sulfate was 5.3 percentage points higher (P=0.17), and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09). The rate of response in the celecoxib control group was 10.0 percentage points higher than that in the placebo control group (P=0.008). For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002). Adverse events were mild, infrequent, and evenly distributed among the groups. Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain. [Clegg DO et al; New Eng J Med 354: 795-808 (2006)]
Biomedical Effects and Toxicity:
Information on the absorption and serum pharmacokinetics for dietary glucosamine is very limited, and in some case, the available data are contradictory. For example, in one series of studies, (14)C-glucosamine was given orally to rats, dogs, and humans, and in all cases, the radiolabel was described as "efficiently" absorbed, reaching a plasma peak after about 4 hours. A high percentage of the radiolabel (about 35%) was excreted in the urine, and a similar amount was last in expired air. On the other hand, the laboratory that conducted this experiment was unable to detect chemical amounts of glucosamine in human serum after a single oral dose at 100 mg/kg (five times the clinical dose) using a chromatographic assay with a limit of detection of about 14 uM. This suggests that the bioavailable glucosamine in human serum after the normal recommended dosage (20 mg/kg) is well below 10 uM.
About 90% of glucosamine administered orally as a glucosamine salt get absorbed from the small intestine, and from there it is transported via the portal circulation to the liver. It appears that a significant fraction of the ingested glucosamine is catabolized by first-pass metabolism in the liver. Free glucosamine is not detected in the serum after oral intake, and it si not presently known how much of an ingested dose is taken up in the joints in humans. Some uptake in the articular cartilage is seen in animal studies.
Twelve healthy volunteers received three consecutive once-daily oral administrations of glucosamine sulfate soluble powder at the doses of 750, 1,500, and 3,000 mg, in an open, randomised, cross-over fashion. Glucosamine was determined in plasma collected up to 48 hr after the last dose. ... Endogenous plasma levels of glucosamine were detected (10.4-204 ng/ml, with low intra-subject variability). Glucosamine was rapidly absorbed after oral administration and its pharmacokinetics were linear in the dose range 750-1,500 mg, but not at 3,000 mg, where the plasma concentration-time profiles were less than expected based on dose-proportionality. Plasma levels increased over 30-folds from baseline and peaked at about 10 microM with the standard 1,500 mg once-daily dosage. Glucosamine distributed to extravascular compartments and its plasma concentrations were still above baseline up to the last collection time. [Persiani S et al; Osteoarthritis Cartilage 13 (12): 1041-9 (2005)] PubMed Abstract
Eighteen subjects with osteoarthritis were given 1,500 mg of commercial glucosamine sulphate after an overnight fast, and serum was then obtained at baseline and every 15-30 minutes over 3 hours, and additionally, from two subjects at 5 and 8 hours. Urine samples were collected at baseline and 3 hours after ingestion from three subjects. Baseline glucosamine was below the detection limit of 0.5 umol/L for all subjects, but after ingestion, glucosamine was detected in 17/18 subjects, beginning to rise at 30-45 minutes to a maximum at 90-180 minutes, with a range of 1.9-11.5 umol/L (0.34-2 ug/ml). [Bittee BA et al; Ann Rheum Dis 65 (2): 222-6 (2006)] PubMed Abstract
The purpose of this study was to determine if glucosamine (GL) hydrochloride (FCHG49) and low molecular weight (LMW) chondroitin sulfate (CS) (TRH122) are absorbed after oral administration to horses. The bioavailability of LMWCS was evaluated by quantifying the total disaccharides found in the plasma following chondroitinase ABC digestion. Two separate studies were conducted. In study 1, ten adult horses received the following four treatments in a randomized crossover fashion: (1) i.v. LMWCS (3 g of 8 kDa), (2) p.o. LMWCS (3 g of 8 kDa), (3) i.v. LMWCS (3 g of 16.9 kDa) and (4) p.o. LMWCS (3 g of 16.9 kDa). Each group received 9 g GL with LMWCS. In a second study, each horse (n=2) was randomly assigned to receive either i.v. administration of GL HCl (9 g) or p.o. administration of GL HCl (125 mg/kg). Blood samples were collected, assayed and pharmacokinetic parameters were determined. GL was absorbed after oral dosing with a mean C(max) of 10.6 (6.9) ug/ml and a mean T(max) of 2.0 (0.7) hr. The extent of absorption of LMWCS after dosing with both the 8.0 and 16.9 kDa provides evidence that LMWCS is absorbed orally. C(max) and AUC were higher (pPubMed Abstract
The purpose of this study was to determine the oral bioavailability and pharmacokinetics of a glucosamine and the disaccharides of chondroitin sulfate after single and multiple-dosing of a glucosamine/chondroitin sulfate combination (Cosamin, Cosequin). Male beagle dogs (n = 8, 12 kg) received the following treatments: (1) IV glucosamine (500 mg)/chondroitin sulfate (400 mg), (2) p.o. glucosamine (1500 mg)/chondroitin sulfate (1200 mg), (3) p.o. glucosamine (2000 mg)/chondroitin sulfate (1600 mg), (4) p.o. glucosamine (1500 mg)/chondroitin sulfate (1200 mg) QD for days 1-7 and p.o. glucosamine (3000 mg)/chondroitin sulfate (2400 mg) from days 8 to 14. Blood samples were collected over 24 hr and glucosamine and the disaccharides of chondroitin sulfate were determined. Pharmacokinetic analysis was performed on glucosamine and total chondroitin sulfate disaccharides and parameters were compared across treatments using ANOVA with post hoc analysis. After the IV administration, glucosamine declined rapidly in a bi-exponential fashion with a mean (+ or - S.D.) elimination t(1/2) of 0.52 (0.25) hr. Glucosamine absorption was relatively fast (C(max) = 8.95 ug/ml, and T(max) 1.5 h after 1500 mg dose) and the mean bioavailability of glucosamine after single dosing was approximately 12%. The extent of absorption of chondroitin sulfate as indicated by the mean C(max) (21.5 ug/ml) and mean AUC (187 ug/ml hr) of total disaccharides after dosing (1600 mg) provides evidence that chondroitin sulfate is absorbed orally. The bioavailability of chondroitin sulfate ranged from 4.8 to 5.0% after single dosing and 200-278% upon multiple dosing. The results of this study show that both glucosamine and chondroitin sulfate (measured as total disaccharides) are bioavailable after oral dosing. In addition, the low molecular weight chondroitin sulfate used in this study displays significant accumulation upon multiple dosing. [Adebowale A et al; Biopharm Drug Dispos 23 (6): 217-25 (2002)] PubMed Abstract
The pharmacokinetics of glucosamine sulfate was investigated in 6 healthy male volunteers (2 per administration route) using (14)C uniformly labelled glucosamine sulfate and administering it in single dose by intravenous (i.v.), intramuscular (i.m.) or oral route. The results show that after i.v. administration the radioactivity due to glucosamine appears in plasma and is rapidly eliminated, with an initial t1/2 of 0.28 hr. 1-2 hr after administration the radioactivity due to glucosamine disappears almost completely and is replaced by a radioactivity originating from plasma proteins, in which glucosamine or its metabolites are incorporated. This radioactivity reaches a peak after 8-10 hr and then declines with a t1/2 of 70 hr. About 28% of the administered radioactivity is recovered in the urine of the 120 hr following the administration and less than 1% is recovered in the feces. After i.m. administration similar pharmacokinetic patterns are observed. After oral administration a proportion close to 90% of glucosamine sulfate is absorbed. Free glucosamine is not detectable in plasma. The radioactivity incorporated in the plasma proteins follows pharmacokinetic patterns which are similar to those after i.v. or i.m. administration, but its concentration in plasma is about 5 times smaller than that after parenteral administration. The AUC after oral administration is 26% of that after i.v., or i.m. administration. The smaller plasma levels of radioactivity after oral administration are probably due to a first pass effect in the liver which metabolizes a notable proportion of glucosamine into smaller molecules and ultimately to CO2, water and urea. [Setnikar I et al; Arzneimittelforschung 43 (10): 1109-13 (1993)] PubMed Abstract
Environmental Fate and Exposure Potential
Environmental Fate/Exposure Summary:
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that glucosamine is expected to have very high mobility in soil(SRC). The pKa of glucosamine is 7.58(3), indicating that this compound will partially exist in cation form in the environment and cations generally absorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the neutral form of glucosamine from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 7.7X10-16 atm-cu m/mole(SRC), using a fragment constant estimation method(5). Volatilization of the cation from moist soil surfaces will not occur as ionic species do not volatilize. Glucosamine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 9.0X10-8 mm Hg(SRC), determined from a fragment constant method(6). Glucosamine is expected to biodegrade fairly rapidly in aerobic soil environments based on a grab sample study using two different soils where 36 and 56% mineralization and 65 and 70% mineralization were reported after 1 and 8 weeks, respectively(7).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 10(SRC), determined from a structure estimation method(2), indicates that glucosamine is not expected to adsorb to suspended solids and sediment(SRC). However, glucosamine will exist partially in the cation form at pH values of 5 to 9 based on a pKa of 7.58(5) and cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(6). Volatilization from water surfaces is not expected(3) for the neutral species based upon an estimated Henry's Law constant of 7.7X10-16 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). Volatilization of the cation from water surfaces is not expected to occur as ionic species do not volatilize. According to a classification scheme(7), an estimated BCF of 3(SRC), from an estimated log Kow of -4.2(8) and a regression-derived equation(9), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Glucosamine is expected to biodegrade fairly rapidly in aerobic water based on a soil grab sample study using two different soils where 36 and 56% mineralization and 65 and 70% mineralization were reported after 1 and 8 weeks, respectively(10).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), glucosamine, which has an estimated vapor pressure of 9.0X10-8 mm Hg at 25 deg C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase glucosamine may be removed from the air by wet or dry deposition(SRC). Glucosamine does not contain a chromophore that absorbs at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(3).
Chemical Company
Qingdao Hua Runde Plastic Machinery Co., Ltd:
Qingdao Hua Runde Plastic Machinery Co., Ltd. is an comprehensive company for scientific research,Website:http://www.plasticextrudermachinery.com, development, production, technical innovation (consultation), sales of plastic machinery. Since the establishment of the company, it is engaged always in the research and development of plastic machinery, digests and absorbs constantly the leading process and technology in the world. Hua Runde products represent the leading level of similar plastic extrusion production lines in China. Based on many years of experience in design and manufacture of extruder, the company can combine perfectly the independent development and foreign advanced technology in plastic processing.? HRD extruding production line series realize both high efficiency and high 
465724SX54ScsdaAD:
 
Ningbo Better-Energy Technology Lighting Co.,Ltd:
Ningbo Better-Energy Technology Lighting Co.,Ltd .is a leading manufacturer & exporter of fluorescent ,Website:http://www.led-wall-pack.com,led and solar in China. We have our own factory and fluorescent factory.All of our products have been in strict Quanlity Control. For Fluorescent Building Department: For fluorescent factory which is found in 1999,our factory have 21 years for CFL Fluorescent experience and also OEM for Philips,OSRAM and also China big brand. For T5 retrofit kits,we also have ETL,FCC,ROHS CE FOR Universe 110-277v and have 6 patents For American market and own successful cased in American ,Canada and south American ,germany and Australia. 
Hebei Shengweilong Commercial&Trade Co.,Ltd:
 
Shenzhen WT Lighting Co.,Ltd WE:
???Yongkang?zhengya?weighing?apparatus?factory?lies?in?the?well-known?hometown?of?hardware China?Science?and?Technology?Hareware?City"?--shiya?Developing?Zone?of?Yongkang?City.? It?is?one?of?the?earliest?factories?producing?weighing?apparatus?in?China.? We?specialize?in?manufacturing?scale?for?more?than?twenty?years.?We?produce?kitchen?scale,Website:http://www.zhengyascale.cc, electronic?scales,?hanging?scale,?spring?scale,and?health?scale?and?many?others.?We?can?also?do?OEM? products?and?if?required.? ?????During?passed?20?years,thanksgiving?all?our?partners?and?customers,we?become?a?leading manufacturer?of?digital?scales?and?mechanical?scale.We?attaches?great?importance?to?quality?control? and?customer?service,that?play?an?important?role?of?our?business.Now?all?of?our?products?have?passe 
Beijing Ribio Biotech Co.,Ltd:
 
Beijing Jinxinxing Medical Device Factory:
 
SHIFANG DETIAN CHEMICAL CO., LTD.:
 
SHENZHNE GENERAL SYSTEMS CO., LIMITED:
Shenzhen General Systems Co., Limited is the global leading Manufacturer of X-ray security screening systems,Website:http://xrayscanner.net/, Explosives & Narcotics Detection, Under Vehicle Surveillance Systems,Automatic Bollards, Road Blockers, Turnstiles, barrier gates, Walk-through Metal Detectors, parking guidance systems, parking management systems etc. with over 25 years experiences and we design, manufacture, market and service our excellent security equipment for years to follow. 
XIAMEN KHAN IMP. & EXP. CO., LTD.:
Xiamen Khan Imp. &lifier exp. CO., Ltd., Established this year, is really a specialized chemical exporter supplying an extensive selection of items.                    
Novartis AG:
Novartis was produced in 1996 with the merger of Ciba-Geigy and Sandoz, two companies having a wealthy and diverse corporate history. Through the years, Novartis and its predecessor companies have found and developed many innovative items for patients and customers worldwide.To understand more about our history and key accomplishments, click the timeline above. 
Shandong Jiulong Fine Chemical CO.,LTD:
 
ningbo GLK biochem ltd:
 
Tianjin YiRuiDa Chemical Co.,LTD:
.Tianjin YiRuiDa Chemical Co., Ltd. is definitely an enterprise which partcipates in worldwide exchange refined chemicals and organic chemical material. It may enjoy all favourable guidelines of Tianjin Port Free Trade Zone with the proper for import and export business, and it's high economic strength.Our primary items range from the basis Inorganic and organic chemicals, dyestuffs and the like, that are utilized in the Paint & Coating Industry, rubber industry, Water-treatment Industry, feed industry, Fertilizer Industry, ETC.Related to the superior quality control, best purchase service, Fast delivery time and Competitive Cost, Our items are offered well and granted high status such nations and regions, as South Usa, Middle East and Southeast Asia and ETC.You're welcome at Tianjin YiRui 
paradise organics:
 
TianJIn TianXiLai chemistry Co.,Ltd:
 
Shaanxi yunzhong industry development co.,Ltd:
Shaanxi Yunzhong Industry Development Co.,Ltd,Website:http://www.yunchtitanium.com,located in Baoji,the leading R & D,production,processing and distribution center of titanium(Ti) in China,is a high-tech enterprise specializing in the research and development,producing as well as processing of such nonferrous materisls mainly as Ti.With decades of nonferrous matarls and their alloys processing research experience,strong technical support,first-class production equipment and testing platform,the company has built a complete and mature titanium manufacturing system to produce and process Ti and its alloys,Tungsten,Molybdenum,Tantalum,Niobium,Zirconium,Hafnium,Nickelof unique and fine specifications.Its products are widely used in aviation,aerospace,navigation,weapons,energy,chemical,metallur 
Yiling Pharma Group:
 
Tianjin Baienwei New Material Technology Co.,Ltd:
Tianjin Baienwei New Material Technology Co., Ltd is a high-tech manufacturer with a collection of R&D,Website:http://www.alsi-alloy.com, production and sales.?The company adopts advanced spray forming technology and specializes in the production of AlSi alloys(also called CE alloys in some countries) and super high strength aluminum alloys(strength≥720MPa). Our main products include: AlSi alloys, electronic packaging housings, auto parts, super high strength aluminum alloy products etc, which are widely used in aerospace, military industry, automotive industry, machinery and heavy industry and other high-end fields?etc.? Baienwei has passed ISO9001:2008 Quality Management System and National Military Standard(GJB). Baienwei offers exclusive and customized services according to customers'  
Zhuhaishi Shuangbojie Technology Co.,Ltd.:
Zhuhaishi Shuangbojie Technology Co.,Ltd. is a leading Chinese chemical supplier special in hormone powder steroids. Resort to its sophisticated technology, the company integrates R&D, producing, operating and marketing into an organic whole. Our company capital asserts is above 300 million RMB. According to the GMP standard, the company has built 30000 sq.m plant equipped the advanced equipment. The factory has a complete Q.A. & Q.C. system. We own several sets of analyzing instruments with high efficiency and high sensitivity, such as HPLC, GC and UV spectrophotometer to analyze and control the products. We have the authority of export and import, and we have passed ISO9001, KOSHER and REACH Submission Report.